Cessation Therapeutics Announces Oral Presentation of Preliminary Findings from First-in-Human Study of Anti-Fentanyl Monoclonal Antibody, CSX-1004
Cessation Therapeutics Receives FDA Fast Track Designation for CSX-1004
Cessation Therapeutics Awarded $14.8 Million Grant from the National Institute of Drug Abuse to Develop Novel Formulation of Anti-Fentanyl Monoclonal Antibody
Dr. Vince Clinical Research Joins the Fight Against the Fentanyl Crisis, Announces Screening of First Subject for Cessation Therapeutics’ Overdose Prevention Therapy in a First-In-Human Trial
Cessation Therapeutics Announces Food and Drug Administration Authorization for First-in-Human Clinical Trial of Antibody for Prevention of Fentanyl Overdose